Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction

This publication has 12 references indexed in Scilit:

• Impaired Myocardial Perfusion Is a Major Explanation of the Poor Outcome Observed in Patients Undergoing Primary Angioplasty for ST-Segment–Elevation Myocardial Infarction and Signs of Heart Failure
  Circulation, 2004
• 833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial
  Journal of the American College of Cardiology, 2004
• Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
  Circulation, 2003
• The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study
  Journal of the American College of Cardiology, 2002
• The inflammatory response in myocardial infarction
  Cardiovascular Research, 2002
• Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction
  Circulation, 2001
• Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial Infarction
  Circulation, 1998
• Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion
  Circulation, 1998
• C-reactive protein and complement in myocardial infarction and postinfarction heart failure
  European Heart Journal, 1997
• Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens: A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial
  Journal of the American College of Cardiology, 1995